Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

5 articles from the last 90 days matching "surgery"

Clinical trialCLINICALTRIALS3 days ago

Trial Now Recruiting: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (NCT06563999)

Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.

WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
You can act on thisNon-small-cell lung cancer (NSCLC), stage III, unresectableRead →
Clinical trialCLINICALTRIALSApr 6

Trial Now Recruiting: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (NCT07128199)

Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.

WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
You can act on thisnon-small cell lung cancerNSCLC with uncommon EGFR mutationsearly-stage lung cancerRead →
Clinical trialUNITERAREApr 3

New Recruiting Trial: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.

WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.
You can act on thisHemophilia ARead →
Clinical trialCLINICALTRIALSApr 1

Trial Now Recruiting: Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors (NCT07374692)

Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.

WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
You can act on thisRecurrent Central Nervous System TumorsBrain CancerGliomasRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Functional and Morphological Characterization of Multiple Osteochondromas Disorder (NCT06703736)

Researchers are looking for 60 people with hereditary multiple osteochondromas (a condition where benign bone tumors grow in multiple places on the body) to join a study. The study will measure how these tumors affect body shape, movement, and function in both children and adults. The goal is to better understand the disease and help doctors decide when surgery is needed.

WHY IT MATTERSThis trial is actively recruiting patients with hereditary multiple osteochondromas and could help establish better guidelines for when surgical treatment should happen, potentially improving outcomes for both pediatric and adult patients.
You can act on thisHereditary Multiple OsteochondromasMultiple Osteochondromas DisorderRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases